Elderly-onset severe parkinsonism in Wilson Disease: Expert Commentary
There are no conflicts of interest and all the authors listed have approved the manuscript that is enclosed. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 21, 2024 Category: Neurology Authors: Laxmi Patil, Gaurav Mehta, Annu Aggarwal Source Type: research
Commentary on: A new genetic variant, presenting as young onset rapidly progressive dementia and parkinsonism
In September edition of Movement Disorders Rounds, Dr. Negin Eissazade et al. describe an interesting young patient who developed a rapidly progressive parkinsonism and dementia syndrome secondary to a novel homozygous missense mutation in the alpha-synuclein (SNCA) gene [1]. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 21, 2024 Category: Neurology Authors: M. Claudia Uribe Roca Source Type: research
Heterozygous APTX mutation associated with atypical multiple system atrophy-like phenotype: A case report
We describe here a 73-years-old patient presenting with atypical MSA-P-like phenotype carrying a monoallelic p. W279X mutation in the APTX gene, which causes ataxia with oculomotor apraxia type 1 (AOA1) when in homozygous state. We hypothesize that rare monoallelic APTX variants could modulate MSA risk and phenotype. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 19, 2024 Category: Neurology Authors: Alberto Imarisio, Andrea Pilotto, Alessandro Lupini, Giorgio Biasiotto, Isabella Zanella, Riccardo Curr ò, Elisa Vegezzi, Andrea Cortese, Ilaria Palmieri, Enza Maria Valente, Alessandro Padovani Tags: Correspondence Source Type: research
Elucidating the association between direct-acting antivirals and Parkinson's disease in patients with hepatitis C virus infection
Some epidemiological studies have found an increased association between Parkinson's disease (PD) and chronic hepatitis C virus (HCV) infection. Although a few studies have also found a decreased risk of PD with interferon- α therapy, the effect of direct-acting antivirals (DAAs) on Parkinson's disease remains unclear. The current study seeks to assess and elucidate the association between DAAs and PD in patients newly diagnosed with chronic HCV infection. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 19, 2024 Category: Neurology Authors: Pilar Hernandez-Con, Raj Desai, David Nelson, Haesuk Park Tags: Short communication Source Type: research
Effects of supplementary Da Dingfeng Zhu therapy on patients with Parkinson's disease of liver-kidney yin deficiency pattern
This study aimed to verify whether the combined use of Da Dingfengzhu and Western medicine in treating Parkinson's disease (PD) can lead to therapeutic efficacy and symptom alleviation, thereby achieving a complementary and synergistic effect. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 17, 2024 Category: Neurology Authors: Meili Liu, Zhiwei Jia, Tianyu Yao, Guoxian Zhang, Xuejing Wang Source Type: research
Differential influences of rest tremor on brain fiber architecture in essential tremor and Parkinson's disease
Rest tremor is a movement disorder commonly found in diseases like Parkinson's disease (PD) and essential tremor (ET). Rest tremor typically shows slower progression in PD, but more severe progression in ET. However, the underlying white matter organization of rest tremor behind PD and ET remains unclear. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 15, 2024 Category: Neurology Authors: Xiaojie Duanmu, Jiaqi Wen, Jianmei Qin, Sijia Tan, Chenqing Wu, Weijin Yuan, Qianshi Zheng, Cheng Zhou, Haoting Wu, Jingwen Chen, Shuyue Wang, Hui Hong, Tao Guo, Jingjing Wu, Bingting Zhu, Yuelin Fang, Yaping Yan, Guohua Zhao, Baorong Zhang, Minming Zhang Source Type: research
Brain-first vs. body-first Parkinson's disease: An update on recent evidence
We recently proposed a new disease model of Parkinson's disease – the a-Synuclein Origin site and Connectome model. The model posits that the initial pathology starts either in the olfactory bulb or amygdala leading to a brain-first subtype, or in the enteric nervous system leading to a body-first subtype. These subtypes should be distinguishable early in the disease course on a range of imaging, clinical, and neuropathological markers. Here, we review recent original human studies, which tested the predictions of the model.Molecular imaging studies were generally in agreement with the model, whereas structural imaging s...
Source: Parkinsonism and Related Disorders - March 15, 2024 Category: Neurology Authors: Jacob Horsager, Per Borghammer Tags: Review article Source Type: research
MRI index of glymphatic system mediates the influence of locus coeruleus on cognition in Parkinson's disease
The objective was to investigate the relationship among LC degeneration, cognitive performance, and the glymphatic function in PD. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 15, 2024 Category: Neurology Authors: Xinhui Wang, Pei Huang, Ewart Mark Haacke, Peng Wu, Xiaobing Zhang, Huihui Zhang, Zenghui Cheng, Rongbiao Tang, Fangtao Liu, Yu Liu, Xiaofeng Shi, Peng Liu, Youmin Zhang, Zhijia Jin, Shengdi Chen, Naying He, Fuhua Yan Tags: Short communication Source Type: research
The role of peripheral inflammation-related biomarkers in distinguishing Parkinson's disease
Peripheral inflammation plays a significant role in Parkinson's disease (PD). Conflicting studies on whether inflammatory indicators in blood could serve as biomarkers to distinguish PD. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 14, 2024 Category: Neurology Authors: Zhuo Zhang, Yue Wang, Jin Wang, Ying Cai, Peipei Liu, Shoufeng Liu, Jialing Wu, Xin Xie Source Type: research
Updates in essential tremor
Essential tremor (ET) is one of the most common tremor disorders and can be disabling in its affect on daily activities. There have been major breakthroughs in the treatment of tremor and ET is the subject of important ongoing research. This review will present recent advancements in the epidemiology, genetics, pathophysiology, diagnosis, comorbidities, and imaging of ET. Current and future treatment options in the management of ET will also be reviewed. The need for continued innovation and scientific inquiry to meet the unmet needs of persons of ET will be highlighted. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 12, 2024 Category: Neurology Authors: Tyler Okelberry, Kelly E. Lyons, Rajesh Pahwa Tags: Review article Source Type: research
OFF episode quality of life impact scale (OFFELIA): A new measure of quality of life for off episodes in Parkinson's disease
OFF Episodes occur in people with Parkinson's disease when their medication wears off, and motor and/or non-motor symptoms emerge. Existing measures used to assess OFF Episodes focus on the time spent in OFF Episodes through diaries or by identifying symptoms, but they are limited in their ability to capture the severity and functional impact of OFF episodes. The aim of this study was to develop and validate a new instrument, called “OFFELIA,” that measures the impact of OFF episodes on the quality of life of individuals with Parkinson's disease. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 12, 2024 Category: Neurology Authors: Maja Kuharic, Victoria Kulbokas, Kent Hanson, Jonathan L. Nazari, Kanya K. Shah, Ai Nguyen, Tara Hensle, Connie Marras, Melissa J. Armstrong, Yash J. Jalundhwala, A. Simon Pickard Source Type: research
Importance of upper and lower body resistance exercise for preventing and reversing sarcopenia in Parkinson ’s disease
The conclusion of the abstract of Kim et al. suggests that High Intensity Interval Training (HIIT) may be superior to Moderate Intensity Continuous Training (MICT) in improving “sarcopenia” in people with Parkinson’s Disease (PwPD) [1]. These findings are potentially important since they show preliminary evidence that HIIT can improve parameters related to “sarcopenia”. However, it is important to note to note that the authors do not directly compare the experime ntal two groups. The HIIT group was only directly compared to the usual care group and did show greater increases in leg lean mass, Appendicular Skeleta...
Source: Parkinsonism and Related Disorders - March 12, 2024 Category: Neurology Authors: Daniel M. Corcos Source Type: research
Deep brain stimulation of the subthalamic nucleus increases the risk of sialorrhea in patients with advanced Parkinson's disease
Sialorrhea is a common neurological manifestation of Parkinson's disease (PD). No specifically designed prospective study has tested the effects of deep brain stimulation of the subthalamic nucleus (STN-DBS) on sialorrhea in patients with advanced PD. We focused on the effect of STN-DBS on the incidence of sialorrhea in patients with PD. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 8, 2024 Category: Neurology Authors: Jinxing Sun, Lian Cheng, Li Zhenke, Junheng Jia, Qianqian Wu, Ying Hou, Qi Wang, Guangjian Zhang, Hong Wang, Xingang Li, Weiguo Li, Chao Zhang Source Type: research
Correlation between clinical and neuropathological subtypes of progressive supranuclear palsy
This study aimed to statistically verify the correspondence between the clinical and pathological subtypes of PSP. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - March 8, 2024 Category: Neurology Authors: Ryuichi Koizumi, Akagi Akio, Yuichi Riku, Hiroaki Miyahara, Jun Sone, Fumiaki Tanaka, Mari Yoshida, Yasushi Iwasaki Source Type: research
Anti-alpha synuclein and anti-tau immunotherapies: Can a cocktail approach work?
The hypothesis that neurodegenerative diseases are proteinopathies due to toxic effect of different underlying proteins, such as amyloid-beta and 3+4R-tau in Alzheimer's disease (AD) and alpha-synuclein in Parkinson's disease (PD), while still controversial is supported by several studies in the literature. This has led to conduct clinical trials attempting to reduce the load of these allegedly toxic proteins by immunotherapy, mostly but not solely based on antibodies against these proteins. Already completed clinical trials have ranged from initially negative results to recently partial positive outcomes, specifically for...
Source: Parkinsonism and Related Disorders - March 7, 2024 Category: Neurology Authors: Kirsys Patricia del Giudice, Marina Cosgaya, Idoia Zaro, Valeria Ravasi, Pilar Santacruz, Celia Painous, Manel Fern ández, Ana Cámara, Yaroslau Compta Tags: Review article Source Type: research
